The in vitro effects of 2-methoxyestradiol-bis-sulphamate on cell numbers, membrane integrity and cell morphology, and the possible induction of apoptosis and autophagy in a non-tumorigenic breast epithelial cell line

• Autorzy: Visagie M. , Joubert A.M.
• Języki publikacji: EN

Abstrakty

EN

2-methoxyestradiol (2ME2) exerts estrogen receptor-independent anti-proliferative, anti-angiogenic and anti-tumor activity in vitro and in vivo. Due to its low bioavailability and rapid metabolic degradation, several analogues have been developed in recent years. 2-methoxyestradiol-bis-sulphamate (2-MeOE2bisMATE) is a bis-sulphamoylated derivative of 2ME2 with anti-proliferative activity. The aim of this study was to investigate cell signaling events induced by 2-MeOE2bisMATE in a non-tumorigenic cell line (MCF-12A) by analysing its influence on cell number, morphology and membrane integrity, and the possible induction of apoptosis and autophagy. Dose- and time-dependent studies revealed that 48 h exposure to 2-MeOE2bisMATE (0.4 μM) resulted in a decrease in cell numbers to 79%. A slight increase in the level of lactate dehydrogenase production was observed in the 2-MeOE2bisMATE-treated cells. Morphological studies revealed an increase in the number of cells in metaphase. Hallmarks of apoptosis were also found, namely nuclear fragmentation and apoptotic bodies. In addition, increased lysosomal staining was observed via fluorescent microscopy, suggesting the induction of another type of cell death, namely autophagy. Since 2-MeOE2bisMATE is regarded as a potential anti-cancer agent, it is also imperative to investigate the susceptibility of non-tumorigenic cells to its influence. The data generated from this study contributes to the understanding of the action that 2-MeOE2bisMATE exerts on the non-tumorigenic MCF-12A breast epithelial cell line.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2010
• Tom: 15
• Numer: 4
• Opis fizyczny: p.564-581,fig.,ref.

Twórcy

autor

Visagie M.

• Department of Physiology, University of Pretoria, Pretoria, P.O. Box 2034, Pretoria, 00001, South Africa

autor

Joubert A.M.

Bibliografia

• 1. Dubey, R.K. and Jackson, E.K. Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol. Metab. 20 (2009) 374-379.
• 2. Pribluda, V.S., Gubish, E.R., La Vallee, T.M., Treston, A., Swartz, G.M and Green, S.J. 2-Methylestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 19 (2000) 173-179.
• 3. Bhati, R., Gokmen-Polar, Y., Sledge, G.W., Fan, C., Nakshatri, H., Ketelsen, D., Borchers, C.H., Dial, M.J., Patterson, C. and Klauber-DeMore, N. 2-Methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells. Cancer Res. 67 (2007) 702-708.
• 4. Banerjee, S.N., Sengupta, K., Banerjee, S., Saxene, N.K. and Banerjee, S.K. 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-α: a possible signaling pathway associated with the impact of 2-ME2 on proliferating cells. Neoplasia 5 (2003) 417-426.
• 5. Funakoshi, T., Birsner, A.E. and D’Amato, R.J. Antiangiogenic effect of oral 2-methoxyestradiol on choroidal neovascularization in mice. Exp. Eye Res. 83 (2006) 1102-1107.
• 6. Matei, D., Schilder, J., Sutton, G., Perkins, S., Breen, T., Quon, C. and Sidor, C. Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A hoosier oncology group trial. Gynaecol. Oncol. 115 (2009) 90-96.
• 7. Lakka, S.S. and Rao, J.S. Angiogenic therapy in brain tumors. Expert Rev. Neurother. 8 (2008) 1457-1473.
• 8. Sutherland, T.E., Anderson, R.L., Hughes, R.A., Altmann, E., Schuliga, M., Ziogas, J. and Stewart, A.G. 2-Methoxyestradiol- a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discov. Today 12 (2007) 577-584.
• 9. Thaver, V., Lottering, M.L., Van Papendorp, D. and Joubert, A. In vitro effects of 2-methoxyestradiol on cell numbers, morphology, cell cycle progression, and apoptosis induction in oesophageal carcinoma cells. Cell Biochem. Funct. 27 (2009) 205-210.
• 10. Lakhani, N.J., Lepper, E.R., Sparreboom, A., Dahut, W.L., Venitz, J. and Figg, W.D. Determination of 2-methxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass. Spectrom. 19 (2005) 1176-1182.
• 11. Foster, P.A., Ho, Y.T., Newman, S.P., Kasprzyk, M.P., Leese, M.P., Potter, B.V., Reed, M.J. and Purohit, A. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res. Treat. 111 (2008) 251-260.
• 12. Reed, M.J., Purohit, A., Woo, L.W.L., Newman, S.P. and Potter, B.V.L. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr. Rev. 26 (2005) 171-202.
• 13. Kirches, E. and Wraich-Kirches, M. 2-Methoxyestradiol as a potential cytostatic drug in gliomas? Anticancer Agents Med. Chem. 9 (2009) 55-65.
• 14. Utsumi, T., Leese, M.P., Chander, S.K., Gaukroger, K., Purohit, A., Newman, S.P., Potter B.V. and Reed, M.J. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells. J. Steroid Biochem. Mol. Biol. 94 (2005) 219-227.
• 15. Tagg, S.L., Foster, P.A., Leese, M.P., Potter, B.V., Reed, M.J., Purohit, A. and Newman, S.P. 2-methoxyoestradiol-3,27-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. Br. J. Cancer 99 (2008) 1842-1848.
• 16. Ireson, C.R., Chander, S.K., Purohit, A., Perera, S., Newman, S.P., Parish, D., Leese, M.P., Smith, A.C., Potter, B.V. and Reed, M.J. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bissulphamate in vivo in rodents. Br. J. Cancer 90 (2004) 932-937.
• 17. Suzuki, R.N., Newman, S.P., Purohit, A., Leese, M.P., Potter, B.V. and Reed, M.J. Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol. 84 (2003) 269-278.
• 18. Foster, P.A., Newman, S.P., Leese, M.P., Bernetiere, S., Diolez, C., Camara, J., Hacher, B., Baronnet, M.M., Ali, T., Potter, B.V., Reed, M.J. and Purohit, A. A new micronized formulation of 2-methoxyestradiol-bis-sulphamate (STX140) is therapeutically potent against breast cancer. Anticancer Res. 28 (2008) 577-581.
• 19. Wood, L., Leese, M.P., Mouzakiti, A., Purohit, A., Potter, B.V., Reed, M.J. and Packham, G. 2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases. Apoptosis 9 (2004) 323-332.
• 20. Newman, S.P., Leese, M.P., Purohit, A., James, D.R.C., Rennie, C.E., Potter, B.V. and Reed, M.J. Inhibition of in vitro angiogenesis by 2-Methoxy- and 2-ethyl-estrogen sulphamates. Int. J. Cancer 109 (2004) 533-540.
• 21. Joubert, A.M., Marais, S. and Maritz, C. Influence of 2-methoxyestradiol on MCF-7 cells: An improved differential interference contrasting technique and Bcl-2 and Bax protein expression levels. Biocell 33 (2009) 67-70.
• 22. Gillies, R.J., Didier, N. and Denton, M. Determination of cell number in monolayer cultures. Anal. Biochem. 159 (1986) 109-113.
• 23. Grever, M.R., Schepartz, S.A. and Chabner, B.A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19 (1992) 622-638.
• 24. Kusuzaki, K., Murata, H., Takeshita, H., Hashiguchi, S., Nozaki, T., Emoto, K., Ashihara, T. and Hirasawa, Y. Intracellular binding sites of acridine orange in living osteosarcoma cells. Anticancer Res. 20 (2000) 971-975.
• 25. Elmore, S. Apoptosis: a Review of programmed cell death. Toxicol. Pathol. 35 (2007) 495-516.
• 26. Xia, GH., Chen, B.A., Shao, Z.Y., Lu, H.X., Konstanze, D. and Hartmut, D. Mechanism of 2-methoxyestradiol-induced apoptosis in myelodysplastic syndrome MUTZ-1 cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15 (2007) 296-301.
• 27. Kachadourian, R., Liochev, S.I., Cabelli, D.E., Patel, M.N., Fridovich, I. and Day, B.J. 2-Methoxyestradiol does not inhibit superoxide dismutase. Arch. Biochem. Biophys. 392 (2001) 349-353.
• 28. Fu, J., Weise, A.M., Falany, J.L., Falany, C.N., Thibodeau, B.J., Miller, F.R., Korarek, T.A. and Runge-Morris, M. Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. Breast Cancer Res. Treat. 120 (2010) 35-40.
• 29. Yoshimura, N., Harada, N., Bukholm, I., Karesen, R., Borresen-Dale, A. and Kristensen, V.N. Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. Breast Cancer Res. 6 (2004) R46-R55.
• 30. Stanway, S.J., Delavault, P., Purohit, A., Woo, L.W., Thurieau, C., Potter, B.V. and Reed, M.J. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 12 (2007) 370-374.

Uwagi

PL

Rekord w opracowaniu.